APA (7th ed.) Citation

MWC, V., C, B., A, L., S, N., L, S., J, F., . . . VHJ, v. d. V. (2022). Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study. British journal of haematology, 197(1), 76. https://doi.org/10.1111/bjh.17992

Chicago Style (17th ed.) Citation

MWC, Verbeek, et al. "Flow Cytometric Minimal Residual Disease Assessment in B-cell Precursor Acute Lymphoblastic Leukaemia Patients Treated with CD19-targeted Therapies - a EuroFlow Study." British Journal of Haematology 197, no. 1 (2022): 76. https://doi.org/10.1111/bjh.17992.

MLA (9th ed.) Citation

MWC, Verbeek, et al. "Flow Cytometric Minimal Residual Disease Assessment in B-cell Precursor Acute Lymphoblastic Leukaemia Patients Treated with CD19-targeted Therapies - a EuroFlow Study." British Journal of Haematology, vol. 197, no. 1, 2022, p. 76, https://doi.org/10.1111/bjh.17992.